Join

Compare · HOWL vs LLY

HOWL vs LLY

Side-by-side comparison of Werewolf Therapeutics Inc. (HOWL) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both HOWL and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • LLY is the larger of the two at $234.46B, about 988.5x HOWL ($237.2M).
  • Over the past year, HOWL is down 0.1% and LLY is up 0.8% - LLY leads by 0.9 points.
  • LLY has hit the wire 10 times in the past 4 weeks while HOWL has been quiet.
  • LLY has more recent analyst coverage (25 ratings vs 6 for HOWL).
PerformanceHOWL-0.12%LLY+0.77%
2025-04-28+0.00%2026-04-24
MetricHOWLLLY
Company
Werewolf Therapeutics Inc.
Eli Lilly and Company
Price
$0.82-5.52%
$884.02-3.63%
Market cap
$237.2M
$234.46B
1M return
+4.68%
-3.48%
1Y return
-0.12%
+0.77%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
0
10
Recent ratings
6
25
HOWL

Werewolf Therapeutics Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

LLY

Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Latest HOWL

Latest LLY